Medtronic, National Institute of Hospital Administration in China Partner for Development of Diabetes Care Pathway
Medtronic, Inc. (NYSE: MDT) announced today it has entered into an innovative partnership with the National Institute of Hospital Administration, an important think tank under China's National Health and Family Planning Commission, to carry out a series of research projects focusing on building an integrated care pathway for patients with Type 1 diabetes. This effort is an example of a partnership focused on working with an important organization to access data that can be used to understand the economic and clinical value of therapies and how they can be best utilized in a patient population.
Both Medtronic and the National Institute of Hospital Administration will participate in establishing pilot sites for the proposed domestic Type 1 diabetes integrated pathway system at 10-12 regional children's hospitals and general hospitals across the country. The goal is to gather insight that can support the foundation of a Chinese nationwide system to improve the treatment of Type 1 diabetes patients and reduce the likelihood of complications among this vulnerable population.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.